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Abstract
Background: Health administrative data were increasingly used for chronic diseases (CDs) surveillance purposes.
This cross sectional study explored the agreement between Belgian compulsory health insurance (BCHI) data and
Belgian health interview survey (BHIS) data for asserting CDs.
Methods: Individual BHIS 2013 data were linked with BCHI data using the unique national register number. The study
population included all participants of the BHIS 2013 aged 15 years and older. Linkage was possible for 93% of BHIS-
participants, resulting in a study sample of 8474 individuals. For seven CDs disease status was available both through self-
reported information from the BHIS and algorithms based on ATC-codes of disease-specific medication, developed on
demand of the National Institute for Health and Disability Insurance (NIHDI). CD prevalence rates from both data sources were
compared. Agreement was measured using sensitivity, specificity, positive predictive value (PPV) and negative predictive value
(NPV) assuming BHIS data as gold standard. Kappa statistic was also calculated. Participants’ sociodemographic and health
status characteristics associated with agreement were tested using logistic regression for each CD.
Results: Prevalence from BCHI data was significantly higher for CVDs but significantly lower for COPD and asthma. No
significant difference was found between the two data sources for the remaining CDs. Sensitivity was 83% for CVDs,
78% for diabetes and ranged from 27 to 67% for the other CDs. Specificity was excellent for all CDs (above 98%) except
for CVDs. The highest PPV was found for Parkinson’s disease (83%) and ranged from 41 to 75% for the remaining CDs.
Irrespective of the CDs, the NPV was excellent. Kappa statistic was good for diabetes, CVDs, Parkinson’s disease and
thyroid disorders, moderate for epilepsy and fair for COPD and asthma. Agreement between BHIS and BCHI data is
affected by individual sociodemographic characteristics and health status, although these effects varied across CDs.
Conclusions: NHIDI’s CDs case definitions are an acceptable alternative to identify cases of diabetes, CVDs, Parkinson’s
disease and thyroid disorders but yield in a significant underestimated number of patients suffering from asthma and
COPD. Further research is needed to refine the definitions of CDs from administrative data.
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Background
Chronic diseases (CDs) represent an important concern
for public health policy. Indeed, their prevalence is con-
stantly increasing and they are by far the leading cause of
mortality in Europe, representing 77% of the total disease
burden and 86% of all deaths [1].
An important prerequisite for the CDs management is
to be able to identify, in a valid, simple and inexpensive
way, the population with CDs that need proactive and
planned care [2]. For this purpose, population-based
data for routine monitoring of CDs prevalence are fun-
damental to describe the burden of disease and to plan
and evaluate disease prevention, treatment and manage-
ment strategies and by defining target populations [3, 4].
Prevalence of CDs is often estimated using population
health surveys, disease registers, hospitalization or out-
patient records [3–8]. Besides these traditional methods,
health administrative databases have been used as an alter-
native, efficient source of data for CDs surveillance [4, 5, 9,
10]. Health administrative databases can be accessed easily
and quickly, associated costs are low and they are quite
exhaustive. In some cases such databases can be used to
provide cross-sectional and longitudinal data on the preva-
lence and incidence of diseases in the entire population
[10]. The use of such data is very challenging [11] yet due
to the opportunity they provide, they have often been used
for surveillance purposes. For instance, in France, the
French national health insurance information system (Sys-
tème National de Données de Santé – SNDS) has been
used to develop the Diabetes National Surveillance System
which serves as a base to estimate the national prevalence
of pharmacologically treated diabetes and the incidence of
diabetes-related complications, as well as their temporal
trends and their territorial variations [12]. To estimate these
indicators, a diabetes case definition algorithm based on an-
tidiabetic drug consumption was applied [4]. Drug use data,
especially prescription drugs, have also been frequently
used to estimate CDs prevalence [5, 7, 13].
In Belgium, the prevalence of specific CDs is usually
assessed, based on data gathered through the Belgian
health interview survey (BHIS), conducted every 5-years.
Next to this, other sources such as hospital discharge data,
disease-specific registries (e.g., Belgian cancer registry), sen-
tinel practice networks (e.g., Intego sentinel GP network),
also represent important tools to obtain prevalence/inci-
dence rates of CDs.
More than 99% of the Belgian population is covered
by the Belgian compulsory health insurance (BCHI). The
BCHI database provides detailed and complete informa-
tion on the reimbursement of health care costs for al-
most the entire population. Such information is widely
used by important actors in the health field, such as the
National Institute for Health and Disability Insurance
(NIHDI), the Belgian health care knowledge centre and
the Federal planning bureau tor studying and planning
topics mainly related to health care costs and expendi-
tures. Although these data are not meant for epidemio-
logical purposes, BCHI data are also used to estimate
the prevalence of some CDs at population level [14].
At the initiative of the NIHDI, a panel of experts (mainly
clinicians) have developed algorithms based on prescribed
medication dispensed in public pharmacies to construct
indicators of CDs. The algorithms are all based on a mini-
mum consumption of 90 DDD (Defined Daily Dose) dur-
ing one calendar year of drugs of certain (sub) classes of
ATC (Anatomical Therapeutic Chemical), often in com-
bination with the minimum age of the patient [15].
These indicators of CDs are useful for the NIHDI, to
identify specific patient populations. However, since their
development, they have only been validated qualitatively.
To our knowledge, only one study has compared the
prevalence of diabetes mellitus and thyroid disorders from
BHIS, BCHI and diagnostic codes in Flanders [6].
The main objective of this study was to assess agree-
ment between health administrative and self-reported
cases definitions of diabetes, asthma, chronic obstructive
pulmonary disease (COPD), cardiovascular diseases in-
cluding hypertension (CVDs), Parkinson’s disease, thyroid
disorders and epilepsy in the Belgian population, assuming
self-reported data as a gold standard. The aforementioned
CDs were chosen because they are common diseases with
a lower risk of misreporting by BHIS participants and be-
cause they are generally treated with specific drugs which
are more or less specific for the disease. Furthermore, we
also sought to determine the subject sociodemographic
and health status characteristics that may affect the agree-
ment between the two data sources.
Methods
Study design and population
This is a descriptive cross-sectional study. The study
population included all participants of the Belgian health
interview survey (BHIS) 2013 aged 15 years and older
(n = 9112).
Data sources
Date were derived from the HISLINK 2013 study, an in-
dividual linkage between the Belgian health interview
survey (BHIS) 2013 data and the Belgian compulsory
health insurance data (BCHI) from 2012 to 2018.
The BHIS is a national, cross-sectional household sur-
vey conducted every 5 years since 1997 by Sciensano, the
Belgian health institute, among a representative sample
of Belgian residents. Participants are selected from the
national population register through a multistage strati-
fied sampling procedure. The participation rate in the
survey was 57% at the household level. In the BHIS, in-
formation is collected on health status, health behavior,
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health care consumption, sociodemographic characteris-
tics and use of medicines. The detailed methodology of
the survey is described elsewhere [16].
The BCHI data contain exhaustive and detailed infor-
mation on the reimbursed health expenses of over 99% of
the total population. The database also includes a limited
amount of socio-demographic information. The BCHI
data were provided by the Intermutualistic Agency (IMA).
IMA is a joint venture of the seven national sickness funds
and collects and manages all data on healthcare expendi-
tures as well as prescription information on reimbursed
medicines (Pharmanet data) [17]. Pharmanet logs all data
on reimbursed dispensed medication from public pharma-
cies in Belgium. Pharmanet data include information on
the date of dispensing, the quantity per package (QPP),
the daily defined dose (DDD) and the national code num-
ber of the medicine (CNK codes) which allows to link
each medicine to its ATC-code. The list of ATC codes per
CNK codes was provided by the NIHDI.
Individual BHIS 2013 data were linked with BCHI data
using the unique national register number. The study
population included all participants of the BHIS 2013 aged
15 years and older (n = 9112). The linkage was possible for
93% of them, resulting in a final sample of 8474 individuals.
The HISLINK 2013 was used because it was the most re-
cent linked database available at the moment of this study.
Identification of chronic diseases
The prevalence information from BHIS was collected
using a list of CDs (35 in total) based on the following
question: “Have you suffered during the last 12 months
from the following disease?”. Since there is no specific indi-
cator for CVDs in the BHIS, we considered a person to
have CVDs (including hypertension) when they reported
having had in the past 12months at least one of the fol-
lowing CDs: myocardial infarction, coronary disease,
hypertension, stroke, or other serious heart diseases.
In the BCHI data, the NIHDI algorithms were used to
ascertained cases of CDs. In these algorithms, CDs cases
were identified based on the ATC-codes of dispensed
medication in public pharmacies, using the WHO guide-
lines on the ATC classification system [18]. So, a CD
was assigned to a participant if the total of DDDs reim-
bursed for all selected ATC-codes used in the treatment
for this CD is greater or equal to 90 [15] in the past 12
months preceding the participation in the BHIS. The se-
lected ATC-codes for each CD are presented in Table 1.
Statistical analyses
We calculated the weighted prevalence rates from both
data sources for the 7 selected CDs. The delta method
[19] was applied to test if there was a significant differ-
ence between the estimates of both sources.
The agreement was measured by estimating sensitivity,
specificity, positive predictive value (PPV) and negative
predictive value (NPV) and their 95% CI, assuming BHIS
data as gold standard. Sensitivity was defined as the per-
centage of true positive cases an algorithm detects among
all positive disease cases. Positive disease cases are BHIS
respondents who reported having the specified disease.
Specificity was defined as the percentage of true negative
cases an algorithm detects among all the negative disease
cases. Negative disease cases are BHIS respondents who
did not report having the specified disease. Positive pre-
dictive values (PPVs) and negative predictive values
(NPVs) are also reported for each chronic disease algo-
rithm. PPV refers to the percentage of individuals with a
positive result for an algorithm among those who reported
having the disease. NPV refers to the percentage of indi-
viduals with a negative result for an algorithm who did
not report having the disease [20].
Furthermore, Kappa values were calculated to differenti-
ate between true agreement and agreement produced by
chance. Kappa values were interpreted as follows: κ ≤ 0.40,
fair-to-poor agreement; κ = 0.41 to 0.60, moderate agree-
ment; κ = 0.61 to 0.80, substantial agreement; and κ = 0.81
to 1.00, almost perfect agreement [21].
Sensitivity analyses were conducted by repeated analyses
for different cut-off points of the DDD for all the CDs.
Table 1 Survey questions and ATC prescription drug codes for
chronic disease case ascertainment, HISLINK 2013, Belgium
Chronic diseases Survey questions:
“Have you suffered during
the last 12months from … “
ATC-codes
Diabetes mellitus Diabetes? A10A
A10B



















Thyroid disorders thyroid disorders? H03AA
a For people aged < = 50 years
b For people aged > 50 years
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Finally, univariable and multivariable logistic regression
analysis were performed for each CD (except for the Par-
kinson’s disease because of small number of cases unable
to provide reliable estimates) to further investigate the ef-
fect of respondent’s characteristics on the total agreement
(true positive or true negative) between BHIS and BCHI
data sources. Participants characteristics included in the
model are: gender, age-group (15–34, 35–54, 55–74 and
75+ years), education (low, intermediate, high), nationality
(Belgian, EU-countries, other countries), household in-
come (quintile), region of residence (Flanders, Brussels,
Wallonia), self-perceived health (good to very good, very
bad to fair), presence of multimorbidity (yes/no) and poly-
pharmacy defined as simultaneous use 5 medicines or
more on a typical day (yes/no).
A two-sided alpha level of 0.05 was considered statisti-
cally significant. All analyses were performed using SAS
9.4 (SAS Institute Inc., Cary, NC, USA) and Stata 16.1
and taking into account the survey settings.
Ethics statement
As mentioned above, this study was carried out using
the individual linkage between the BHIS 2013 data and
the BCHI data. The BHIS 2013 was carried out in line
with the Belgian privacy legislation and has been ap-
proved by the ethics committee of the University hos-
pital of Ghent on October, 1st 2012 (advice EC UZG
2012/658). The participation to BHIS is voluntary. There
was no formal written and signed consent foreseen as
participation was considered as consent. In addition, for
the data linkage, an authorization was obtained from the
Information Security Committee (local reference: Delib-
eration No. 17/119 of December 19, 2017, amended on
September 3, 2019).
This study is reported according to the STROBE
statement.
Results
Table 1 summarizes the CDs with identification ques-
tions in the BHIS data source and the assigned ATC-
codes in the BCHI data source.
Characteristics of the study population, unweighted and
weighted to reflect the general Belgian population in terms
of age, gender and region are presented in Table A1 (sup-
plementary material). More than half of the population
perceived their health to be good to very good, 15% suffers
from multimorbidity and one person out of ten simul-
taneous uses 5 medicines or more on a one day refer-
ence period.
Table 2 shows the prevalence of CDs in the population
by data source. The prevalence rates obtained from ad-
ministrative data source were significantly higher than
those obtained from survey data for CVDs (including
hypertension), but on the contrary, they were significantly
lower for COPD and asthma. No significant difference
was found between the two data sources for the remaining
CDs.
The agreement measures are described in Table 3.
Sensitivity was good for CVDs (83%), fair for diabetes
(78%) and poor for all other CDs (value varying between
27 and 67%). The specificity was excellent for all CDs
(specificity above 98%) except for CVDs (specificity =
89%). The PPV was poor to fair for all the CDs (PPV
varying between 41 and 75%), except for Parkinson’s dis-
ease where it was good (PPV = 83%). Irrespective of the
CDs, the NPV was excellent (NPV varying between 96
and 99%). The Kappa statistic was good for diabetes,
CVDs, Parkinson’s disease and thyroid disorders (kappa
between 0.63 and 0.77), moderate for epilepsy (kappa =
0.46) and fair for COPD and asthma (kappa = 0.35).
The results of the sensitivity analysis are presented in
Fig. 1. Across the CDs, the sensitivity decreased with the
increase of the cut-off point of the DDD, while the PPV
slightly increased after the threshold of 90 DDD. Notable
Table 2 Prevalence (weighted percentages) of chronic diseases among the population aged 15 years and over by data source, HISL
INK 2013, Belgium








% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Diabetes mellitus 5.46 (4.78 to 6.15) 5.69 (5.05 to 6.33) −2.25 (−1.13 to 6.84) −3.96 (− 19.65 to 11.73)
CVDsa 19.15 (17.88 to 20.42) 25.09 (23.68 to 26.51) −5.94 (−7.68 to −4.20) − 23.68 (− 29.79 to − 17.57)
COPDa 4.01 (3.45 to 4.56) 2.82 (2.35 to 3.29) 1.19 (0.47 to 1.90) 42.10 (11.85 to 72.35)
Asthmaa 4.36 (3.77 to 4.96) 1.64 (1.29 to 1.99) 2.72 (2.05 to 3.39) 165.82 (99.15 to 232.49)
Parkinson’s disease 0.50 (0.28 to 0.71) 0.38 (0.21 to 0.55) 0.11 (− 0.16 to 0.39) 29.77 (− 50.95 to 110.49)
Epilepsy 0.94 (0.64 to1.24) 1.33 (1.03 to 1.68) −0.38 (− 0.80 to 0.03) −28.98 (− 55.85 to 2.13)
Thyroid disorders 5.89 (5.20 to 6.58) 5.43 (4.78 to 6.08) 0.46 (−0.49 to 1.42) 8.57 (−97.72 to 26.91)
aDenotes significant difference between BHIS prevalence en BCHI prevalence
bComputed before rounded the estimated prevalences
CVDs cardiovascular diseases (including hypertension), COPD chronic obstructive pulmonary disease
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for Parkinson’s disease was the highest PPV around 320
DDDs and for thyroid disorders was the lowest PPV
around 220 DDDs.
Table 4 shows the results from the multivariable logistic
regression, while the unadjusted odds ratios are presented
in additional Table A2 (supplementary material). Table 4
shows that the agreement between BHIS and BCHI data
sources is affected by individual sociodemographic charac-
teristics and health status. However, the characteristics
which are associated, the magnitude and direction of the
effect varied across CDs. For instance, gender was not sig-
nificantly associated with the agreement between BHIS
and BCHI data except for thyroid disorders where the
agreement was significantly lower among women (OR:
0.26, 95% CI: 0.17–0.40). Compared to the reference age-
group (55–74 years), belonging to the youngest age-group
(15–34 years) was associated with a greater level of agree-
ment between the data sources for diabetes (OR: 6.40,
95% CI: 2.38–17.25), CVDs (OR: 8.63, 95% CI: 5.56–
13.39) and thyroid disorders (OR: 2.76, 95% CI: 1.54–
4.95), while the reverse is true for asthma (OR: 0.19, 95%
CI: 0.10–0.36). Regarding participant’s health status,
people with a relatively good subjective health, those with-
out multimorbidity and those who didn’t simultaneous
use 5 medicines or more on a typical day (polypharmacy)
have greater odds of agreement between the two sources
except for CVDs where the absence of multimorbidity was
significantly associated with a lower odds of agreement.
Discussion
In this study we assessed agreement between population-
based administrative and survey data for ascertaining cases
of diabetes, asthma, chronic obstructive pulmonary dis-
ease, cardiovascular diseases (including hypertension),
Parkinson’s disease, thyroid disorders and epilepsy, for
which BHIS data served as the gold standard. We also
investigated the individual characteristics that could influ-
ence the agreement between both data sources.
Using the two data sources, we obtained inconsistent
prevalence estimates in 3 out of the 7 CDs studied. Specific-
ally, in CVDs (including hypertension), the prevalence was
significantly higher in the BCHI data than in the BHIS data,
while the inverse was true for COPD and asthma. The high
prevalence of CVDs (including hypertension) according to
the BCHI source (25%) compared to the BHIS prevalence
(19%) could be explained by the use of drugs in this ATC
group for other problems such as a high serum cholesterol
for example. Some drugs may be assigned to two chronic
diseases simultaneously, for example, beta-blockers are pre-
scribed both for patients with hypertension and in patients
with heart problems. As mentioned by Huber et al. in their
study, an unique assignment of ATC-codes to heart diseases
is challenging, and with the new trends in the use of various
drugs for cardiac and hypertensive patients, a clear distinc-
tion between ATC-codes for cardiac diseases and hyperten-
sion is infeasible [9]. Therefore, we included hypertension in
the BHIS based case definition of CVDs. The low preva-
lence of COPD and asthma in the administrative data could
be explained by the fact that some people suffering from
asthma or COPD do not necessarily take medications or
less than 90 DDDs per year.
The estimated prevalence rate of diabetes mellitus from
BCHI data is comparable to the one estimated in similar
studies using health administrative database [9, 10, 22, 23],
but higher than those in others comparable studies [5, 13].
Moreover, the prevalence of the respiratory illness
(COPD, asthma) from BCHI is also comparable to those
in similar in Netherlands, Italy and Swedish [5, 13, 24, 25].
Regarding the prevalence of Parkinson disease, thyroid
disorders and Epilepsy, our results are in line with those
reported by Francesco Chini et al. in Italy using a pre-
scribed database [13] and by Huber et al. in Switzerland
using medical and pharmacy claims data [9]. Considering
the CVDs (including hypertension), our estimated preva-
lence was lower than the prevalence obtained by Huber
et al. (29%) based on pharmacy data [9]. This difference
could be explained by the CDs case definition used in
Table 3 Agreement between self-reported chronic disease and definitions from administrative data, HISLINK 2013, Belgium*










Diabetes mellitus 78.5 (72.1–85.0) 98.5 (98.2–98.9) 75.4 (70.5–80.3) 98.8 (98.3–99.2) 0.77 (0.75–0.80)
CVDs 83.1 (80.6–85.6) 88.6 (87.6–89.7) 63.4 (60.6–66.2) 95.7 (95.0–96.3) 0.63 (0.61–0.65)
COPD 28.8 (22.3–35.3) 98.3 (97.9–98.6) 40.9 (32.5–49.3) 97.1 (96.6–97.5) 0.35 (0.30–0.40)
Asthma 27.4 (21.3–33.6) 99.5 (99.3–99.7) 72.9 (63.8–82.1) 96.8 (96.2–97.3) 0.35 (0.30–0.41)
Parkinson’s disease 64.3 (38.9–89.8) 99.9 (99.9–100) 83.5 (69.8–97.3) 99.8 (99.7–100) 0.70 (0.58–0.82)
Epilepsy 60.4 (44.6–76.2) 99.2 (99.0–99.4) 42.9 (31.0–54.8) 99.6 (99.4–99.8) 0.46 (0.37–0.55)
Thyroid disorders 66.7 (61.0–72.4) 98.4 (98.1–98.7) 72.4 (67.3–77.5) 97.9 (97.5–98.3) 0.66 (0.62–0.69)
CVDs cardiovascular diseases (including hypertension), COPD chronic obstructive pulmonary disease, PPV positive predictive value, NPV negative predictive value
* Sensitivity, specificity, PPV and NPV presented with self-reported as the referent
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their study: people were considered as having CD if they
have at least one prescription in one of the generated
ATC-groups CDs at the end of the reference year, while
our definition was more selective (at least 90 DDDs per
year which could correspond to several prescriptions (if
small package) or more or less 3 months treatment per
the given year.
We found that sensitivity of administrative CDs was
good-to-fair for diabetes and CVDs and poor for the
remaining CDs. Not surprisingly, the lowest sensitivity
Diabetes Cardiovascular diseases
Asthma




Fig. 1 Sensitivity analysis: validity measures of chronic diseases as a function of the DDD threshold, HISLINK 2013. DDD = Daily Defined Dose
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was for COPD and asthma. The sensitivity drop with the
increase of the cut-off point of DDD, while the PPV
increase.
CDs that are more prevalent or that are symptom-
based may also be more reliably self-reported [26]. In
our definition of CVDs in BHIS data source, we included
hypertension, which may have contributed to increase
the agreement between both data sources for CVDs.
The lower sensitivity of asthma (27.4%) in contrast
with its relatively higher PPV (72.9%) in this study could
be explained by the fact that most of the people suffering
from a less severe case of asthma could not take up to
Table 4 Odds Ratios* (95% CIs) for predictors of agreement between administrative and survey data for chronic diseases, HISLINK
2013, Belgium
Diabetes CVDs COPD Asthma Thyroid disorders
Gender
Male Ref. Ref. Ref. Ref. Ref.
Female 1.21 (0.71–2.06) 0.92 (0.73–1.15) 0.89 (0.62–1.27) 1.28 (0.88–1.86) 0.26 (0.17–0.40)a
Age group
15–34 6.40 (2.38–17.25)a 8.63 (5.56–13.39)a 1.19 (0.55–2.56) 0.19 (0.10–0.36)a 2.76 (1.54–4.95)a
35–54 1.09 (0.56–2.10) 2.02 (1.50–2.72)a 0.81 (0.51–1.26) 0.51 (0.30–0.87)a 1.59 (0.98–2.58)
55–74 Ref. Ref. Ref. Ref. Ref.
75+ 1.16 (0.54–2.47) 0.47 (0.35–0.63)a 0.98 (0.61–1.55) 2.09 (1.13–3.84)a 1.01 (0.60–1.69)
Education
Low Ref. Ref. Ref. Ref. Ref.
Intermediate 0.81 (0.42–1.57) 1.19 (0.89–1.60) 1.13 (0.75–1.70) 1.72 (1.08–2.74)* 1.08 (0.70–1.72)
High 1.55 (0.78–3.10) 1.08 (0.76–1.51) 2.07 (1.30–3.32)a 1.52 (0.89–2.59) 1.24 (0.75–2.06)
Nationality
Belgian 2.57 (0.60–10.98) 0.76 (0.26–2.24) 0.28 (0.09–0.83)a 0.64 (0.29–1.42) 2.43 (0.95–6.25)
EU-countries 2.82 (0.52–15.35) 1.37 (0.43–4.32) 0.36 (0.10–1.29) 0.61 (0.18–2.05) 7.15 (1.68–30.51)a
Other countries Ref. Ref. Ref. Ref. Ref.
Income
Quintile 1 Ref. Ref. Ref. Ref. Ref.
Quintile 2 0.63 (0.31–1.27) 0.99 (0.70–1.39) 0.92 (0.55–1.55) 0.94 (0.54–1.63) 0.61 (0.36–1.06)
Quintile 3 1.29 (0.53–3.17) 0.99 (0.69–1.41) 1.17 (0.68–2.02) 1.05 (0.60–1.84) 0.6 (0.36–1.14)
Quintile 4 1.33 (0.64–2.77) 1.25 (0.86–1.81) 1.11 (0.61–2.03) 1.29 (0.69–2.40) 0.69 (0.37–1.28)
Quintile 5 1.05 (0.43–2.51) 1.16 (0.77–1.74) 1.34 (0.69–2.57) 0.70 (0.35–1.40) 1.37 (0.69–2.72)
Region
Flanders 1.25 (0.74–2.09) 1.27 (1.02–1.59)a 1.64 (1.13–2.39)a 1.82 (1.20–2.75)a 2.50 (1.72–3.64)*
Brussels 1.70 (0.84–3.44) 1.06 (0.79–1.43) 1.29 (0.83–1.99) 1.03 (0.62–1.72) 2.30 (1.41–3.75)a
Wallonia Ref. Ref. Ref. Ref. Ref.
Perceived health
Good to very good 0.97 (0.57–1.65) 1.64 (1.26–2.14)a 1.76 (1.23–2.54)a 1.61 (1.10–2.36)a 1.10 (0.71–1.70)
Very bad to fair Ref. Ref. Ref. Ref. Ref.
Multimorbidity
Yes Ref. Ref. Ref. Ref. Ref.
No 5.97 (3.06–11.67)a 0.47 (0.32–0.71)a 6.22 (3.86–10.03)* 15.40 (9.40–25.22)a 1.02 (0.61–1.71)
Polypharmacy
Yes Ref. Ref. Ref. Ref. Ref.
No 1.43 (0.77–2.68) 2.03 (1.42–2.90)a 1.26 (0.81–1.98) 0.70 (0.43–1.14) 2.59 (1.46–4.60)a
CVDs cardiovascular diseases (including hypertension), COPD chronic obstructive pulmonary disease; a Denotes significant difference between this group and the
reference group. * adjusted for all other variables
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90 DDDs of the specific medication per year and those
who reach that cut-off are certainly positive cases. Fur-
thermore, in an exploratory analysis (results not shown),
we found that 3 persons out of 10 suffering from this
CD did not contact a health care professional in the past
12 months for that condition.
The agreement between the two data sources varies by
participants’ sociodemographic characteristics and health
status. However, this moderating effect varies in magni-
tude across CDs. Our results are consistent with findings
in previous studies [3, 8, 27]. For instance, Lix et al.
found that agreement between self-reported and medical
records of chronic conditions was higher among younger
age-groups and in the absence of comorbidity [3].
This study presents a number of strengths that deserve to
be highlighted. First, the large sample size and the use of
comprehensive administrative data, covering 99% of the
Belgian population. It should be noted that not all countries
have the opportunity to have such data. Thus, the existence
of rich and detailed health insurance administrative data
covering almost the entire population constitutes an added
value for public health research in Belgium. Second, we cal-
culated five agreement measures to enable comparison be-
tween data sources. Third, using individual record linkage,
we further examined predictors that could affect the agree-
ment between both data sources.
A number of limitations should also be acknowledged.
One of the main limitations is that the case definition of
CDs in the administrative data source was based on pre-
scription drug codes dispensed in public pharmacies only
and therefore drugs dispensed in the hospital settings were
not included. Another limitation is the lack of additional
information such as ICD-10 codes or other clinical diag-
nostic codes in the case ascertainment from administrative
data source. Indeed, validation studies often include infor-
mation from various sources in the algorithms: health sur-
veys, ICD-10 codes, ATC codes, other clinical diagnostic
codes, etc., and this provides much better measures of
agreement [2, 3, 7, 10]. Finally, the BHIS data was used as
the gold standard in this study because next to administra-
tive data, it is the only source for obtaining population-
based chronic disease prevalence estimates in Belgium. We
acknowledged that self-reported data may not be an un-
biased gold standard due to the risk of under-reporting or
over-reporting of some chronic diseases. However, self-
reported data have been used in previous studies to assess
the validity of health administrative databases [20, 28, 29]
and have shown higher agreement between these sources
for chronic diseases that are more familiar to patients, well
defined and require ongoing management [3, 20, 28, 30,
31]. Keeping this in mind, the CDs discussed in this study
are sufficiently well known and defined that the risk of pro-
viding erroneous information from BHIS participants is
negligible. Moreover, several studies have assessed the
specificity of self-reported CDs compared to clinical diag-
noses or medical records and have found that the specifi-
city was at least 80% for asthma, hypertension, severe heart
disease or heart attack, stroke, diabetes mellitus, epilepsy,
and Parkinson’s disease [32].
Conclusions
In conclusion, NHIDI’s algorithms are an acceptable al-
ternative for the identification of cases of diabetes, car-
diovascular diseases (without distinction of the different
pathologies), Parkinson’s disease and thyroid disorders.
On the basis of the current definition of CDs from BCHI
data source, there is a significant underestimation of the
number of patients suffering from asthma and COPD.
Further research is needed to refine the definitions of
CDs from administrative data by using other compara-
tors (clinical data, data from general practitioners such
as the Intego registry) or using different thresholds to
enhance NIHDI algorithms.
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